Switzerland· 68297002
Columvi 10 mg/10 ml, Konzentrat zur Herstellung einer Infusionslösung
A glofitamab product containing glofitamabum, registered in Switzerland by Roche Pharma (Schweiz) AG and dispensed under Swissmedic category A. The same ATC class is registered in 13 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Glofitamab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX28 (glofitamab), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Glofitamab · ATC L01FX28
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- glofitamabum
- Manufacturer
- Roche Pharma (Schweiz) AG
- Country
- Switzerland (CH)
- ATC code
- L01FX28
- ATC class
- Glofitamab
- Defined daily dose
- 1.43 mg, P
- Swissmedic category
- A
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Glofitamab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesColumviGenentech, Inc.
- CanadaCOLUMVIHOFFMANN-LA ROCHE LIMITED
- CzechiaCOLUMVIRoche Registration GmbH, Grenzach-Wyhlen
- SpainCOLUMVI 10 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- FinlandColumviRoche Registration GmbH
- FranceCOLUMVI 10 mg, solution à diluer pour perfusionROCHE REGISTRATION (ALLEMAGNE)
- BelgiumColumvi 10 mgRoche Registration
- IrelandColumvi 10 mg concentrate for solution for infusionRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Columvi
- Liechtenstein · Columvi
- Norway · Columvi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/abf44fde-eb76-4f4b-9b02-ed6e7aea15db GET /v1/drugs/abf44fde-eb76-4f4b-9b02-ed6e7aea15db?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Biotechnologika"
}See everything about glofitamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.